Abstract
SUMOylation has emerged as an important post-translational modification that involves the covalent attachment of the Small Ubiquitin-like Modifier (SUMO) polypeptide to a lysine residue of a target protein. The enzymatic pathway of SUMOylation is very similar to ubiquitinylation and involves an activating enzyme, a conjugating enzyme, ligases, and deconjugating enzymes. SUMOylation modulates the function of a number of proteins associated with various pathways, and in fact, dysregulation of the SUMOylation pathway is observed in both cancer and neurological diseases. In many cancers, the SUMO enzymes are upregulated, and SUMO levels correlate directly with prognosis and disease progression. As a result, there has been an emphasis on the discovery and development of inhibitors of SUMOylation. In this review, the latest advances in SUMOylation inhibitors are described alongside the methods used to discover small molecule SUMOylation inhibitors, which include natural products, peptidomimetics, as well as synthetic derivatives identified via virtual screens.
Keywords: SUMO, cancer, ubiquitin-like, post-translational modifications, natural products, small-molecules, enzyme inhibitors.
Current Medicinal Chemistry
Title:Current Status of SUMOylation Inhibitors
Volume: 28 Issue: 20
Author(s): Christopher M. Brackett and Brian S.J. Blagg*
Affiliation:
- Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana 46556,United States
Keywords: SUMO, cancer, ubiquitin-like, post-translational modifications, natural products, small-molecules, enzyme inhibitors.
Abstract: SUMOylation has emerged as an important post-translational modification that involves the covalent attachment of the Small Ubiquitin-like Modifier (SUMO) polypeptide to a lysine residue of a target protein. The enzymatic pathway of SUMOylation is very similar to ubiquitinylation and involves an activating enzyme, a conjugating enzyme, ligases, and deconjugating enzymes. SUMOylation modulates the function of a number of proteins associated with various pathways, and in fact, dysregulation of the SUMOylation pathway is observed in both cancer and neurological diseases. In many cancers, the SUMO enzymes are upregulated, and SUMO levels correlate directly with prognosis and disease progression. As a result, there has been an emphasis on the discovery and development of inhibitors of SUMOylation. In this review, the latest advances in SUMOylation inhibitors are described alongside the methods used to discover small molecule SUMOylation inhibitors, which include natural products, peptidomimetics, as well as synthetic derivatives identified via virtual screens.
Export Options
About this article
Cite this article as:
Brackett M. Christopher and Blagg S.J. Brian *, Current Status of SUMOylation Inhibitors, Current Medicinal Chemistry 2021; 28 (20) . https://dx.doi.org/10.2174/0929867327666200810135039
DOI https://dx.doi.org/10.2174/0929867327666200810135039 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Seeing Genes at Work in the Living Brain with Non-Invasive Molecular Imaging
Current Gene Therapy Cellular Functions of Vaults and their Involvement in Multidrug Resistance
Current Drug Targets Regenerative Medicine: Does Erythropoietin have a Role?
Current Pharmaceutical Design Notch Signaling Proteins: Legitimate Targets for Cancer Therapy
Current Protein & Peptide Science Rational Combination of Targeted Therapies As A Strategy to Overcome The Mechanisms of Resistance to Inhibitors of EGFR Signaling
Current Pharmaceutical Design New Insights into Neoangiogenesis and Breast Cancer Development and Progression
Current Angiogenesis (Discontinued) MicroRNA-155 Functions as a Negative Regulator of RhoA Signaling in TGF-β-induced Endothelial to Mesenchymal Transition
MicroRNA Reversing Breast Cancer Stem Cell into Breast Somatic Stem Cell
Current Pharmaceutical Biotechnology Antisense Treatment in Human Prostate Cancer and Melanoma
Current Cancer Drug Targets Angiogenic and Vascular Modulation by Extracellular Matrix Cleavage Products
Current Pharmaceutical Design Metalloproteinases and Metalloproteinase Inhibitors in Age-Related Diseases
Current Pharmaceutical Design The Role of the Calcium-Sensing Receptor in Bone Biology and Pathophysiology
Current Pharmaceutical Biotechnology Nano Drug Delivery in Treatment of Oral Cancer, A Review of the Literature
Current Drug Targets Off-Label Use of Sunitinib in Patients with Advanced, Epithelial Thyroid Cancer: A Retrospective Analysis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Two Branched Polar Groups and Polar Linker Moieties of Thiophene Amide Derivatives Are Essential for MRP2/ABCC2 Recognition
Drug Metabolism Letters Erbin, a Negative Regulator in Diverse Signal Pathways
Current Protein & Peptide Science Engineering Tissue Model for Anti-Breast Cancer Pharmacotherapy
Current Tissue Engineering (Discontinued) Targeting Toll-Like Receptor Signaling Pathways for Design of Novel Immune Therapeutics
Current Drug Discovery Technologies Polyphenol Supplementation as a Complementary Medicinal Approach to Treating Inflammatory Bowel Disease
Current Medicinal Chemistry T-type Calcium Channels in Health and Disease
Current Medicinal Chemistry